Enhancing anti-angiogenic immunotherapy for melanoma through injectable metal–organic framework hydrogel co-delivery of combretastatin A4 and poly(I:C)-Reference-Cited by-同舟云学术

Enhancing anti-angiogenic immunotherapy for melanoma through injectable metal–organic framework hydrogel co-delivery of combretastatin A4 and poly(I:C)

Published:2024 Issue:12 Volume:6 Page:3135-3145
ISSN:2516-0230
Container-title:Nanoscale Advances
language:en
Short-container-title:Nanoscale Adv.

Author:

Xiao Xufeng¹,Zheng Yunuo²,Wang Tianlong¹,Zhang Xiaoqing¹,Fang Gaochuan¹,Zhang Zhonghai¹,Zhang Zhengkui³⁴,Zhao Jiaojiao¹^ORCID

Affiliation:

1. Jiangsu Key Laboratory of Phylogenomics and Comparative Genomics, Jiangsu International Joint Center of Genomics, School of Life Sciences, Jiangsu Normal University, Xuzhou, 221116, Jiangsu, China

2. Department of Obstetrics and Gynecology, Xuzhou Central Hospital, Xuzhou, 221009, Jiangsu, China

3. Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China

4. Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, Jiangsu, China

Abstract

The combination approach utilizing a ZIF-8/HA injectable hydrogel to co-deliver CA4 and PIC can enhance therapeutic effects by inhibiting tumor vascularization and boosting macrophage-mediated anti-tumor responses.

Funder

Natural Science Foundation of Jiangsu Province

Priority Academic Program Development of Jiangsu Higher Education Institutions

Natural Science Foundation of Xuzhou Municipality

Natural Science Research of Jiangsu Higher Education Institutions of China

High Level Innovation and Entrepreneurial Research Team Program in Jiangsu

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/NA/D4NA00079J

Reference37 articles.

1. Cutaneous melanoma

2. Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction

3. Overcoming Immune Evasion in Melanoma

4. Immune checkpoint inhibitors in melanoma

5. Combination strategies to maximize the benefits of cancer immunotherapy